StreetInsider.com News Articles

Form 4 LABCORP HOLDINGS INC. For: Sep 01 Filed by: Oyegunwa Akinbolade

Thu, 03 Sep 2026 08:21:00 -0400

si-local-file:///var/storage/secattach/20260903/27022361.html

Form 4 LABCORP HOLDINGS INC. For: Sep 01 Filed by: Meltzer Jonathan C

Thu, 03 Sep 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20260903/27022358.html

Form 4 LABCORP HOLDINGS INC. For: Sep 01 Filed by: Vaughn Bryan T

Thu, 03 Sep 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260903/27022355.html

Form 4 LABCORP HOLDINGS INC. For: Sep 01 Filed by: Caveney Brian J

Thu, 03 Sep 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260903/27022285.html

Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity

Mon, 31 Aug 2026 07:00:00 -0400

Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making

BURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies,

Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity

Mon, 31 Aug 2026 07:00:00 -0400

Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making

Form 8-K LABCORP HOLDINGS INC. For: Aug 28

Fri, 28 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26993378.html

Form 8-K LABCORP HOLDINGS INC. For: Aug 28

Fri, 28 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26993378.html

Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

Fri, 28 Aug 2026 08:30:00 -0400

BURLINGTON, N.C., Aug. 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET.

Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

Fri, 28 Aug 2026 08:30:00 -0400

Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

Fri, 28 Aug 2026 08:30:00 -0400

Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

Fri, 28 Aug 2026 08:30:00 -0400

Labcorp to offer FDA-cleared Alzheimer's blood test nationwide

Mon, 24 Aug 2026 07:03:30 -0400

Labcorp (NYSE: LH) announced it will offer the Elecsys® pTau-217 blood test, developed by Roche Diagnostics, following clearance by the U.S. Food and Drug Administration.

According to a company statement, the test is intended for individuals 55 and older who show signs, symptoms, or complaints of cognitive decline. It measures phosphorylated Tau 217 (pTau-217), a biomarker associated with amyloid pathology linked to Alzheimer's disease.

Labcorp describes the Elecsys® pTau-217 as the first and only FDA-cleared single-biomarker blood test capable of both ruling in and ruling out amyloid pathology across primary and specialty care settings. The test uses the same clinical cutoffs in

Labcorp to offer FDA-cleared Alzheimer's blood test nationwide

Mon, 24 Aug 2026 07:03:30 -0400

Labcorp (NYSE: LH) announced it will offer the Elecsys® pTau-217 blood test, developed by Roche Diagnostics, following clearance by the U.S. Food and Drug Administration.

Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings